Payment overview · 2025
General Payments
$1,100.53
61 reported records · 19 companies
Healthcare provider profile · identity verified
Nicholas L Fox, DO
Allopathic & Osteopathic Physicians|Family Medicine · KENDALLVILLE, IN · NPI 1780178004
Verified facts
What the public records show
CMS Open Payments records show Nicholas L Fox, DO received $1,100.53 in general payments during 2025 across 61 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.04 | 19.6% | 17 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $139.93 | 12.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.33 | 9.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.25 | 6.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.82 | 6.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.97 | 6.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.81 | 5.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.85 | 4.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.04 | 4.1% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $42.99 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.98 | 3.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.26 | 3.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.85 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.68 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.65 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.75 | 1.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.80 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.95 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.58 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,100.53 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $122.36 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.68 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.28 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.82 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.66 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.35 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.73 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $28.40 | 2 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $28.40 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.04 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $6.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
251 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
214 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 890 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 689 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 658 | 163 |
| Lisinopril | Lisinopril | 540 | 148 |
| Metformin Hcl | Metformin Hcl | 410 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 403 | 108 |
| Losartan Potassium | Losartan Potassium | 396 | 114 |
| Omeprazole | Omeprazole | 366 | 114 |
| Gabapentin | Gabapentin | 326 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 320 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 277 | 84 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 271 | 83 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 251 | 44 |
| Furosemide | Furosemide | 245 | 58 |
| Carvedilol | Carvedilol | 232 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 56 |
| Mounjaro | Tirzepatide | 214 | 39 |
| Simvastatin | Simvastatin | 210 | 48 |
| Alprazolam | Alprazolam | 204 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 48 |
| Famotidine | Famotidine | 187 | 51 |
| Montelukast Sodium | Montelukast Sodium | 178 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 61 |
| Sertraline Hcl | Sertraline Hcl | 166 | 41 |
| Ozempic | Semaglutide | 159 | 35 |
| Trazodone Hcl | Trazodone Hcl | 153 | 45 |
| Glipizide Er | Glipizide | 143 | 41 |
| Metformin Hcl Er | Metformin Hcl | 143 | 44 |
| Potassium Chloride | Potassium Chloride | 140 | 40 |
| Jardiance | Empagliflozin | 134 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 19 |
| Allopurinol | Allopurinol | 91 | 24 |
| Atenolol | Atenolol | 87 | 25 |
| Januvia | Sitagliptin Phosphate | 86 | 22 |
| Eliquis | Apixaban | 83 | 23 |
| Pregabalin | Pregabalin | 82 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 28 |
| Meloxicam | Meloxicam | 81 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 27 |
| Valsartan | Valsartan | 74 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 19 |
| Synthroid | Levothyroxine Sodium | 71 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 19 |
| Glimepiride | Glimepiride | 70 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 25 |
| Chlorthalidone | Chlorthalidone | 68 | 24 |
| Naproxen | Naproxen | 65 | 20 |
| Bupropion Xl | Bupropion Hcl | 64 | 19 |
| Finasteride | Finasteride | 63 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 20 |
| Myrbetriq | Mirabegron | 60 | 18 |
| Spironolactone | Spironolactone | 58 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 57 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 56 | 16 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 15 |
| Buspirone Hcl | Buspirone Hcl | 48 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 15 |
| Ondansetron Odt | Ondansetron | 48 | 19 |
| Glipizide | Glipizide | 46 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 14 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 28 |
| Nitroglycerin | Nitroglycerin | 41 | 14 |
| Prednisone | Prednisone | 41 | 30 |
| Donepezil Hcl | Donepezil Hcl | 38 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Lovastatin | Lovastatin | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Nystatin | Nystatin | 33 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Gemtesa | Vibegron | 27 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Dayvigo | Lemborexant | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,100.53 · 61 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, Azstarys, BEXSERO, BEYFORTUS, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ENFLONSIA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, PEDIARIX, PENMENVY, QULIPTA, REXULTI, ROTARIX, Rybelsus, SHINGRIX, Symbravo, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error